Looking to defend its giant cardiometabolic health franchise, Eli Lilly is licensing a technology from Swedish biotechnology firm Camurus that promises to produce longer-acting medications ...

Eli Lilly ( LLY 0.64%) has been one of the best-performing pharmaceutical leaders in the past five years. Thanks to strong ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic health. The collaboration and licence agreement gives Lilly exclusive global ...

Partnership focused on development of long-acting therapies based on Camurus' FluidCrystal® technology and Eli Lilly's proprietary drug compoundsCamurus eligible to receive up to $870 million in ...

Camurus (OTC:CAMRF) is a biopharmaceutical company that develops and commercializes medicines for severe and chronic diseases globally. While Eli Lilly and Company (NYSE:LLY) discovers, develops ...

Camurus AB (CAMRF) reports a 52% revenue increase, strategic licensing with Eli Lilly, and EU approval of Oczyesa, despite currency challenges and market hurdles.